



What is it famous for? While being
the main UK government’s agency
for funding biomedical research, it is
probably best known for having
nurtured British molecular biology
in Cambridge in the golden decade
of the 1950s — whence came the
double helix model of DNA (James
Watson and Francis Crick), the first
amino-acid sequence of a protein
(insulin, Fred Sanger), and the first
three-dimensional protein structures
(myoglobin, John Kendrew, and
haemoglobin, Max Perutz).
What has it done since?  It continues
to be the main source of public
funding for biomedical sciences in
the UK, distributing around
£300 million a year to grant holders
and staff in universities, to about 500
graduate students a year, and to over
3 500 staff in over 40 MRC
establishments. However, financial
pressures last year forced the MRC
to reject 70 % of its alpha-rated grant
applications and to warn of the
damaging impact of this level of
rejection.
Where is it?  The other big UK
research councils have moved their
head offices from London to save
costs but not the MRC: it still
occupies a grand building in the
heart of London, half way between
Madame Tussauds waxworks and the
BBC. Its major research
establishments are the National
Institute for Medical Research in
north London (£25 million), the
Laboratory of Molecular Biology in
Cambridge (£13.5 million) and the
Clinical Sciences Centre in west
London (£11 million).
Who runs it?  The UK government
hands over the money, but how it is
spent is decided by the MRC itself.
Overall policy is in the hands of the
17 council members, who are mainly
eminent medics. The current Chief
Executive is a Welsh chemist turned
cell biologist, Sir David (Dai) Rees,
who hands over to a Hungarian
chemist turned biochemist, Professor
György (George) Radda, in October.
Radda left Hungary to take a
chemistry degree at Oxford
University in 1960. He has remained
there ever since, working largely on
the development of magnetic
resonance spectroscopy and its
application to metabolic diseases,
and now holds the title of Professor
of Molecular Cardiology.
What is its biggest success?
Historically, and arguably still, the
Laboratory of Molecular Biology.
The five scientists named in the first
paragraph each received a Nobel
prize, and three more have since
been notched up by the laboratory’s
staff: Cesar Milstein (monoclonal
antibodies), Aaron Klug (structural
studies), and a second to Fred Sanger
(DNA sequencing).
What is its biggest failure?  Probably
the Clinical Research Centre, which
was a bold attempt to attach clinical
research to an ordinary hospital, as
opposed to a teaching- and research-
based hospital. It has recently closed,
and the MRC has instead built the
Clinical Sciences Centre at the
highly research-oriented Royal
Postgraduate Medical School. 
Where is its remotest outpost?  In
The Gambia, a tiny west African
country (and former British colony)
best known as a winter holiday
resort. But away from the beaches
are the MRC Laboratories,
renowned for their laboratory and
field work on malaria. In a test
involving 40 000 children in 100
villages, for example, staff at the
laboratories recently showed that a
large reduction in child mortality
from malaria could be achieved by
dipping bednets in insecticide.
Electronic jottings
Even more than the photocopier, electronic
mail has made it possible to forward lists,
jokes and assorted ephemera to any number
if colleagues (whether they want them or
not). Such electronic jottings seem to
constitute a prolific new life form: they are
spontaneously generated and reproduce
parthenogenetically. Here, we publish one
example; we are not aware of any copyright
held for this item.
A scientist’s view of
intellectual property rights
1. If I like it, it’s mine.
2. If it’s in my hand, it’s mine.
3. If I can take it from you, it’s mine.
4. If I had it a little while ago, it’s
mine.
5. If it’s mine, then it must not
appear to be yours in any way.
6. If I’m doing or building
something, then all the pieces
are mine.
7. If it looks just like mine, it is
mine.
8. If it’s brilliant, it must be mine.
9. If I thought of it once upon a
time, you may not publish it at
any time.
10. If it is so obvious that I should
have thought of it first, it must
be mine as well.
11. If it’s in a manuscript I review,
it’s mine.
12. If it appears to be yours, there
must be some mistake.
Magazine 495
The editors of Current Biology welcome
correspondence on any article in the
journal, but reserve the right to reduce the
length of any letter to be published. Items
for publication should either be submitted
typed, double-spaced, or sent by electronic
mail, to Current Biology, Middlesex House,
34–42 Cleveland Street, London W1P
6LB, UK; fax: 44-171-580-8167; e-mail:
cbiol@cursci.co.uk; they should include a
full contact address, with phone and fax
numbers. A newsgroup-style discussion
page for Current Biology can be found,
along with the journal itself, on the internet,
at http://BioMedNet.com/
